Dossier assessment
Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Selpercatinib (nicht-kleinzelliges Lungenkarzinom) - Nutzenbewertung gemäß § 35a SGB V
-
Dossier assessment
Selpercatinib (nicht-kleinzelliges Lungenkarzinom) - Nutzenbewertung gemäß § 35a SGB V
Dossier assessment
Adult patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy
After first-line therapy with a PD-1/PD-L1 antibody as monotherapy: added benefit not proven.
After first-line therapy with cytotoxic chemotherapy: added benefit not proven.
After first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy: added benefit not proven.
Project details
- Project no.
- A21-27
- Commission
- Commission awarded on 12.03.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (RET fusion-positive NSCLC, first line) - Benefit assessment according to § 35a Social Code Book V (expiry of the limitation period)
Status: Commission completed
-
Dossier assessment
Selpercatinib (RET mutant medullary thyroid cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (thyroid cancer) - Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (solid tumours) - Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (thyroid cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selpercatinib (advanced NSCLC with RET fusion) – Benefit assessment according to § 35a SGB V
Status: Commission completed